Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAnavex Life Sciences Corp

Anavex Life Sciences Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.255 USD 0.10 ( 9.13%)
Last update at 2026-11-09T17:47:00Z
VOLUME
312912
Market Cap
710.59M

Momentum Score

…

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.13
Low
1.26
High
52 Week Price Range
3.25
Low
10.45
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Anavex Life Sciences is a clinical‑stage biopharmaceutical company developing small‑molecule therapies for neurodegenerative and central nervous system disorders, with a lead program (blarcamesine/ANAVEX2‑73) targeting sigma‑1 receptor and muscarinic pathways. Long‑term growth drivers include successful late‑stage clinical results and regulatory progress for lead programs and rising demand for Alzheimer's treatments; investors may view upside in its differentiated mechanism and multi‑indication pipeline.
Primary investment risks are high clinical and regulatory uncertainty for lead candidates, no meaningful product revenues to date, and ongoing financing risk that could dilute shareholders.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.15
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-30.03%
Net Debt
-151.02M
ROCE
-33.48%
Diluted EPS TTM
-0.51

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax -47.50M -47.62M -37.64M -26.26M -26.21M
Net income -47.49M -47.98M -37.91M -26.28M -26.29M
Selling general administrative 12.04M 13.07M 9.02M 5.86M 6.85M
Ebit - -54.40M -41.92M -30.76M -28.75M
Ebitda -47.50M -50.08M -41.68M -31.06M -28.88M
Depreciation and amortization - 4.31M 0.24M -0.31M -0.13M
Non operating income net other - 2.42M 4.33M 4.65M 2.69M
Operating income -47.50M -54.40M -41.92M -30.76M -28.75M
Other operating expenses 55.76M 50.99M 41.95M 30.94M 28.81M
Interest expense 0.96M 0.95M 4.04M 4.81M 2.67M
Tax provision 0.01M 0.36M 0.27M 0.02M 0.08M
Interest income 6.52M 0.95M 0.03M 0.18M 0.21M
Net interest income 5.55M 0.95M 0.03M 0.18M 0.06M
Income tax expense -0.01M 0.36M 0.27M 0.02M 0.08M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 55.76M 50.99M 41.95M 30.94M 28.81M
Total other income expense net 2.68M 6.78M 4.28M 4.50M 2.54M
Net income from continuing ops -47.51M -47.98M -37.91M -26.28M -26.29M
Net income applicable to common shares - -47.98M -37.91M -26.28M -26.29M
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 154.39M 152.70M 161.62M 34.54M 25.33M
Other current assets 0.65M 0.35M 0.37M 0.44M 3.14M
Total liab 12.53M 10.21M 10.80M 7.31M 5.04M
Total stockholder equity 141.85M 142.49M 150.82M 27.24M 20.29M
Deferred long term liab - 0.44M 0.44M - -
Other current liab 7.29M 5.94M 5.61M 3.32M 1.52M
Common stock 0.08M 0.08M 0.08M 0.06M 0.05M
Capital stock 0.08M 0.08M 0.08M 0.06M 0.05M
Retained earnings -293.07M -245.56M -197.59M -159.68M -133.40M
Other assets 3.36M 3546.74M 9.51M 5.29M -
Cash 151.02M 149.16M 152.11M 29.25M 22.19M
Total current liabilities 12.53M 10.21M 10.80M 7.31M 5.04M
Current deferred revenue 0.92M 0.44M 0.44M - -
Net debt -151.02M -149.16M -152.11M -29.25M -22.19M
Other stockholder equity 434.84M 387.98M 348.33M 186.85M 153.63M
Total current assets 154.39M 152.70M 161.62M 34.54M 25.33M
Net tangible assets - 142.49M 150.82M 27.24M 20.29M
Net receivables 2.71M 3.19M 9.14M 4.85M 2.64M
Inventory - - - - -2.64M
Accounts payable 4.32M 3.82M 4.74M 3.99M 3.52M
Common stock total equity - 0.08M 0.08M 0.06M 0.05M
Retained earnings total equity - -245.56M -197.59M -159.68M -133.40M
Non currrent assets other - - 0.02M - 0.00M
Non current assets total 0.00M 0.00M 0.02M 0.00M 0.00M
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Change to liabilities - -0.92M 1.19M 2.27M 1.27M
Net borrowings - - - - -0.05M
Total cash from financing activities 29.65M 21.29M 153.24M 28.35M 17.78M
Change to operating activities - 6.28M -1.90M -0.35M 0.62M
Net income -47.51M -47.98M -37.91M -26.28M -26.29M
Change in cash 1.87M -2.95M 122.86M 7.06M -0.75M
Begin period cash flow 149.16M 152.11M 29.25M 22.19M 22.93M
End period cash flow 151.02M 149.16M 152.11M 29.25M 22.19M
Total cash from operating activities -27.79M -24.24M -30.38M -21.29M -18.53M
Issuance of capital stock 27.88M 20.98M 153.22M 28.75M 17.83M
Change to account receivables - - - -2.21M -
Sale purchase of stock - 21.29M 153.24M 28.35M 17.83M
Other cashflows from financing activities 1.78M 0.30M 0.02M -0.40M -0.05M
Change to netincome - 18.38M 8.23M 4.88M 6.32M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change receivables - - - - -0.77M
Cash flows other operating - 5.95M -3.76M -2.15M 0.95M
Cash and cash equivalents changes - -2.95M 122.86M 7.06M -0.75M
Change in working capital 2.50M 5.36M -0.71M 0.12M 1.30M
Stock based compensation 16.37M 18.38M 8.23M 4.88M 6.43M
Other non cash items 0.84M - 31.18M -6.83M 0.04M
Free cash flow -27.79M -24.24M -30.38M -21.29M -18.53M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
AVXL
Anavex Life Sciences Corp		 0.10
9.13%		 1.25 - - - 5.42 -5.54
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

630 5th Avenue, New York, NY, United States, 10111

844 689 3939

https://www.anavex.com

40

Name Title Year Born
Dr. Christopher U. Missling M.B.A., M.S., Ph.D. Chairman, Pres, CEO & Sec. 1966
Ms. Sandra Boenisch CPA, CPA, CGA Principal Financial Officer & Treasurer 1981
Mr. Stephan Toutain Chief Operating Officer 1966
Dr. Walter E. Kaufmann M.D. Chief Scientific Officer NA
Dr. Emmanuel O. Fadiran RPh, Ph.D. Sr. VP of Regulatory Affairs NA
Clint Tomlinson VP of Corp. NA
Dr. Adebayo Laniyonu Ph.D. Sr. VP of Nonclinical Devel. NA
Dr. Edward R Hammond M.D., M.P.H., Ph.D. Chief Medical Officer NA
Dr. Christopher U. Missling M.B.A., M.S., Ph.D. President, CEO, Secretary & Director 1966
Ms. Sandra Boenisch CPA, CGA Principal Financial Officer & Treasurer 1981

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…